misleading guidance

Rosen Law Firm files securities class action against $GPK, alleging false statements on financial performance and operations. Investors may pursue compensation.

Schall Law Firm investigates Qiagen for alleged securities fraud over QuantiFERON guidance collapse—February projections of 6-7% growth reversed to flat in April.

Law firm seeks lead plaintiffs in securities fraud class action against $GO, alleging concealment of deteriorating metrics and unsustainable expansion before 27.9% stock crash.

Stellantis faces class action lawsuit after €22B charge disclosure triggered 23.69% stock plunge. Company's mid-single-digit margin guidance proved unachievable versus 0.7% actual performance.

Medpace Holdings faces securities lawsuit over allegedly inflated Q4 2025 guidance. Stock dropped 15.9% after actual book-to-bill ratio fell short of management projections.

Eos Energy shareholders must file by May 5, 2026, to join securities class action alleging false production capacity and battery performance claims.

Class action lawsuit filed against Boston Scientific alleging materially false statements about U.S. electrophysiology segment growth. Investors who purchased BSX shares July 2025-February 2026 eligible.

monday.com faces securities fraud lawsuit after retracting $1.8B revenue target. Stock crashed from $189.59 to $77.63 on alleged management misstatements.

Class action lawsuit filed against $BSX alleging material misstatements about U.S. electrophysiology segment growth. Eligible period: July 23, 2025 to February 3, 2026.

$SES plunged 36.8% March 5 after weak Q4 results and 2026 guidance. Class action investigation underway alleging misleading analyst information.

Class action lawsuit filed against $BSX alleging materially false statements about electrophysiology segment growth. Investors from July 2025-February 2026 may be eligible.

Levi & Korsinsky files securities fraud suit against Gartner ($IT) for allegedly concealing deteriorating contract value growth, citing 52% stock decline.

Upstart Holdings faces class action lawsuit alleging misleading statements about AI Model 22's performance. Stock fell 9.71% after November disclosure of model calibration issues.

Stellantis faces securities fraud class action after stock plummeted 23.69% following disclosure of €22 billion in charges and business reset amid misrepresented electrification strategy.

Boston Scientific faces class action lawsuit alleging material misstatements about U.S. electrophysiology segment. Investors from July 2025-February 2026 may have claims; May 4, 2026 deadline to apply as lead plaintiff.

Medpace faces class action suit alleging false guidance on cancellation rates. Stock plunged 15.9% after Q4 2025 miss, triggering investor claims.

PayPal Holdings faces class action lawsuit alleging false revenue guidance. Stock fell over 20% after disappointing Q4 results and CEO transition. Lead plaintiff deadline is April 20, 2026.

Robbins LLP filed class action lawsuit against $MEDP for allegedly misleading investors about book-to-bill guidance, triggering 15.9% stock decline.

Coty Inc. faces securities fraud lawsuit alleging misleading growth guidance before 22% stock plunge. Law firm seeks class action damages.

Medpace Holdings faces $MEDP class action lawsuit after stock plunges 15.9% due to book-to-bill ratio guidance miss: 1.04x actual vs. 1.15x guided.